Eli Lilly and Company (LLY) : 9 brokerage houses believe that Eli Lilly and Company (LLY) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Eli Lilly and Company (LLY). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 14 Wall Street Analysts endorse the stock as a Buy with a rating of 1.86.
Eli Lilly and Company (LLY) : The consensus price target for Eli Lilly and Company (LLY) is $95.42 for the short term with a standard deviation of $16.37. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $116, however, the pessimist price target for the company is $55.
For the current week, the company shares have a recommendation consensus of Buy. Eli Lilly and Company (NYSE:LLY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.98 and $79.98 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.67. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.56, notching a gain of 0.65% for the day. The total traded volume was 2,407,996 . The stock had closed at $80.04 on the previous day.
In a related news,The officer (Chief Accounting Officer) of Lilly Eli & Co, Zakrowski Donald A sold 1,213 shares at $83.16 on July 28, 2016. The Insider selling transaction had a total value worth of $100,873. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.